Alphamab Oncology (HKSE:09966) Earnings per Share (Diluted) : HK$-0.24 (TTM As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Earnings per Share (Diluted)?

Alphamab Oncology's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was HK$-0.04. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-0.24.

Alphamab Oncology's EPS (Basic) for the six months ended in Jun. 2023 was HK$-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-0.24.

Alphamab Oncology's EPS without NRI for the six months ended in Jun. 2023 was HK$-0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-0.24.

During the past 3 years, the average EPS without NRIGrowth Rate was 39.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -52.60% per year.

During the past 7 years, Alphamab Oncology's highest 3-Year average EPS without NRI Growth Rate was 39.30% per year. The lowest was -132.60% per year. And the median was -75.70% per year.

Alphamab Oncology Earnings per Share (Diluted) Historical Data

The historical data trend for Alphamab Oncology's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Earnings per Share (Diluted) Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-1.73

-0.55

-0.54

-0.39

-0.24

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial								-0.18	-0.19	-0.21	-0.04	-0.20

Competitive Comparison of Alphamab Oncology's Earnings per Share (Diluted)

For the Biotechnology subindustry, Alphamab Oncology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's PE Ratio distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's PE Ratio falls into.

Alphamab Oncology Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Alphamab Oncology's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-363.739	-	0)	/	936.502
	=	-0.39

Alphamab Oncology's Earnings Per Share (Diluted) for the quarter that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-43.6	-	0)	/	957.141
	=	-0.05

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.24

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Alphamab Oncology (HKSE:09966) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Alphamab Oncology Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines